Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Tarih
2023Yazar
Karacin, CengizÖksüzoğlu, Berna
Demirci, Ayşe
Keskinkılıç, Merve
Baytemür, Naziyet Köse
Yılmaz, Funda
Selvi, Oğuzhan
Erdem, Dilek
Avşar, Esin
Paksoy, Nail
Demir, Necla
Göksu, Sema Sezgin
Türker, Sema
Bayram, Ertuğrul
Çelebi, Abdüssamet
Yılmaz, Hatice
Kuzu, Ömer Faruk
Kahraman, Seda
Gökmen, İvo
Sakin, Abdullah
Üst veri
Tüm öğe kaydını gösterKünye
Karacin, C., Öksüzoğlu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F. ... Sakin, A. (2023). Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer, 23(1). https://doi.org/10.1186/s12885-023-10609-8Özet
Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.
WoS Q Kategorisi
Q2Scopus Q Kategorisi
Q1Kaynak
BMC CancerCilt
23Sayı
1Koleksiyonlar
- Makale Koleksiyonu [3691]
- PubMed İndeksli Yayınlar Koleksiyonu [4105]
- Scopus İndeksli Yayınlar Koleksiyonu [6383]
- WoS İndeksli Yayınlar Koleksiyonu [6506]